ArticleAmerican journal of hematology2010

TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.

Vijay Ramakrishnan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.